Literature DB >> 9951775

Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat.

P H Watson1, L J Fraher, M Kisiel, D DeSousa, G Hendy, A B Hodsman.   

Abstract

Rats and humans respond to intermittent treatment with parathyroid hormone (PTH) with increased bone density and cancellous bone volume. In the rat, osteoblast expression of insulin-like growth factor-I (IGF-I) is elevated by intermittent PTH. We examined the effect of continuous infusion of rhPTH(1-84), a bone catabolic regime, on the IGF system in rat pelvis. Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump. After 7 days, blood was taken for serum chemistry and pelvises were processed for immunocytochemistry. Sections of pelvis from rats continuously infused with 0.1 or 1 microg/100 g b.w. rhPTH(1-84) for 7 days did not differ significantly from those of the vehicle-treated controls. However, continuous infusion of 5 microg/100 g b.w. rhPTH(1-84) resulted in a dramatic increase in cellular development, with trabeculae surrounded by many layers of large, plump osteoblasts. All pelvis osteoblasts expressed osteocalcin, but only those from rats that received 0, 0.1, or 1 microg/100 g b.w. rhPTH(1-84) showed positive staining for IGF-I. The extra-abundant osteoblasts from rats that received 5 microg/100 g b.w. rhPTH(1-84) did not stain for IGF-I. However, although all osteoblasts stained positively for IGF binding proteins (IGFBPs)-3, -4, and -5, staining for these IGFBPs increased as the dose of rhPTH(1-84) (and osteoblast number) increased. These results suggest that continuous infusion of PTH has a direct effect on osteoblast development (either recruitment or proliferation), decreases the expression of IGF-I, and enhances the expression of IGFBPs in pelvis, factors which may interact to bring about negative bone balance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9951775     DOI: 10.1016/s8756-3282(98)00170-7

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  3 in total

Review 1.  Stemming bone loss by suppressing apoptosis.

Authors:  J M Hock
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 2.  The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.

Authors:  J F Whitfield; P Morley; G E Willick
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

3.  Catabolic Effects of Human PTH (1-34) on Bone: Requirement of Monocyte Chemoattractant Protein-1 in Murine Model of Hyperparathyroidism.

Authors:  Jawed A Siddiqui; Joshua Johnson; Carole Le Henaff; Claudine L Bitel; Joseph A Tamasi; Nicola C Partridge
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.